CO2018007251A2 - Métodos y composiciones para el tratamiento del síndrome de hunter - Google Patents

Métodos y composiciones para el tratamiento del síndrome de hunter

Info

Publication number
CO2018007251A2
CO2018007251A2 CONC2018/0007251A CO2018007251A CO2018007251A2 CO 2018007251 A2 CO2018007251 A2 CO 2018007251A2 CO 2018007251 A CO2018007251 A CO 2018007251A CO 2018007251 A2 CO2018007251 A2 CO 2018007251A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
hunter syndrome
treatment
present
Prior art date
Application number
CONC2018/0007251A
Other languages
English (en)
Inventor
Han-Yeul Byun
Kyu-Hyun Lee
Torayuki Okuyama
Thong-Gyu Jin
Jin-Wook Seo
Byoung-Ju Lee
Yong-Chul Kim
In-Young Jang
Original Assignee
Medigenebio Corp
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigenebio Corp, Green Cross Corp filed Critical Medigenebio Corp
Publication of CO2018007251A2 publication Critical patent/CO2018007251A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona, entre otras cosas, composiciones y métodos para la administración al SNC de Idursulfasa-beta, una proteína iduronato-2-sulfatasa recombinante humana, para el tratamiento eficaz del Síndrome de Hunter. Las composiciones y los métodos proporcionados por la presente invención reducen eficazmente los síntomas no solo en el cerebro y la médula espinal sino también en los tejidos periféricos que incluyen corazón, hígado, bazo, pulmón y riñón.
CONC2018/0007251A 2015-12-30 2018-07-11 Métodos y composiciones para el tratamiento del síndrome de hunter CO2018007251A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562272843P 2015-12-30 2015-12-30
US201662369970P 2016-08-02 2016-08-02
PCT/KR2016/015060 WO2017116066A1 (en) 2015-12-30 2016-12-21 Methods and compositions for treating hunter syndrome

Publications (1)

Publication Number Publication Date
CO2018007251A2 true CO2018007251A2 (es) 2018-07-19

Family

ID=59224844

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007251A CO2018007251A2 (es) 2015-12-30 2018-07-11 Métodos y composiciones para el tratamiento del síndrome de hunter

Country Status (23)

Country Link
US (1) US11052135B2 (es)
EP (1) EP3397270B1 (es)
JP (2) JP2019504053A (es)
KR (2) KR102272399B1 (es)
CN (1) CN108430494A (es)
BR (1) BR112018013421A2 (es)
CL (1) CL2018001782A1 (es)
CO (1) CO2018007251A2 (es)
DK (1) DK3397270T3 (es)
EA (1) EA201891533A1 (es)
FI (1) FI3397270T3 (es)
HK (1) HK1258054A1 (es)
MX (1) MX2018008029A (es)
MY (1) MY193846A (es)
PE (1) PE20181329A1 (es)
PH (1) PH12018550102A1 (es)
PL (1) PL3397270T3 (es)
PT (1) PT3397270T (es)
RS (1) RS65513B1 (es)
SG (1) SG11201805598WA (es)
SI (1) SI3397270T1 (es)
UA (1) UA123704C2 (es)
WO (1) WO2017116066A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201925236A (zh) 2017-10-02 2019-07-01 美商戴納立製藥公司 包含酶替代療法酶之融合蛋白
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US9283181B2 (en) 2010-06-25 2016-03-15 Shire Human Genetic Therapies, Inc. CNS delivery of therapeutic agents
LT3103469T (lt) 2010-06-25 2021-03-25 Shire Human Genetic Therapies, Inc. Terapinių agentų pristatymas cns
RS59469B1 (sr) * 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
PT2672985T (pt) 2011-02-11 2016-07-25 Swedish Orphan Biovitrum Ab (Publ) Composições farmacêuticas compreendendo anakinra sem citrato
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
EA201792099A1 (ru) 2011-12-23 2018-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
CA2868466A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase

Also Published As

Publication number Publication date
UA123704C2 (uk) 2021-05-19
EP3397270A4 (en) 2019-09-18
KR20180090387A (ko) 2018-08-10
RS65513B1 (sr) 2024-06-28
KR20200099621A (ko) 2020-08-24
MX2018008029A (es) 2018-08-23
WO2017116066A1 (en) 2017-07-06
US11052135B2 (en) 2021-07-06
MY193846A (en) 2022-10-28
JP6987924B2 (ja) 2022-01-05
CL2018001782A1 (es) 2018-11-09
EP3397270A1 (en) 2018-11-07
EP3397270B1 (en) 2024-04-17
US20200268857A1 (en) 2020-08-27
FI3397270T3 (fi) 2024-05-10
JP2019504053A (ja) 2019-02-14
PT3397270T (pt) 2024-05-09
PL3397270T3 (pl) 2024-08-19
SI3397270T1 (sl) 2024-07-31
KR102272399B1 (ko) 2021-07-05
DK3397270T3 (da) 2024-05-06
EA201891533A1 (ru) 2018-12-28
SG11201805598WA (en) 2018-07-30
CN108430494A (zh) 2018-08-21
PE20181329A1 (es) 2018-08-20
HK1258054A1 (zh) 2019-11-01
JP2020147578A (ja) 2020-09-17
BR112018013421A2 (pt) 2018-12-18
PH12018550102A1 (en) 2019-02-11

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891152A1 (ru) Экстрацеллюлярные везикулы нервных клеток
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX363182B (es) Composiciones que comprenden mezclas de alcanos semifluorados.
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
GT201300215A (es) Inhibidores de glucosilceramida sintasa
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
BR112017005202A2 (pt) anticorpos anti-met e composições
EA201591925A1 (ru) Терапевтические композиции и их применение
UY37038A (es) Composiciones y métodos para disminuir la expresión de tau
CO2019006979A2 (es) Tratamiento de enfermedades neurológicas
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201691567A1 (ru) Способы лечения легких травм головного мозга
CY1120906T1 (el) Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2018007251A2 (es) Métodos y composiciones para el tratamiento del síndrome de hunter
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
MX345534B (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака